Why Some Medical Devices Change Healthcare While Others Never Do

The first implantable pacemaker was introduced in Sweden in 1958. By today's standards, the technology was remarkably primitive. The first implanted device functioned for only a few hours before it had to be replaced the following day. Few medical technologies would survive such a beginning today, yet history rarely remembers the shortcomings of those first devices. It remembers something else entirely.^¹

For the first time, patients with complete heart block had a treatment that could fundamentally alter the course of their disease. The engineering still needed refinement, but the clinical need was so obvious that few questioned whether the technology belonged in healthcare. The discussion was never really about adoption. It was about how quickly the technology could evolve to fulfil its potential.

Mechanical thrombectomy followed a remarkably different path. The idea was equally compelling, but compelling ideas do not automatically change clinical practice. Early studies failed to provide convincing evidence, patient selection was inconsistent and the technology itself was still developing. For several years, the field progressed slowly despite the promise of the concept.

When landmark studies such as MR CLEAN and SWIFT PRIME were published in 2015, the picture changed. Better imaging made it possible to identify the right patients, the devices themselves had matured and study design had improved considerably. The evidence became difficult to ignore. Treatment guidelines changed, hospitals reorganised stroke pathways and what had once been regarded as an experimental intervention rapidly became standard care for selected patients.^{² ³}

These stories are separated by more than half a century, yet they illustrate the same principle. Medical technologies rarely become successful because they are innovative. They become successful because they solve a problem that healthcare recognises, and because the evidence eventually becomes compelling enough to justify changing established practice.

That distinction is becoming increasingly relevant.

Healthcare has always embraced innovation, but it does so cautiously. Clinical routines, treatment guidelines and hospital quality systems have evolved over decades for good reasons. Changing them carries both cost and risk. Every new technology therefore competes not only with existing products but with existing behaviour, and changing behaviour is often considerably more difficult than improving technology.

Against that backdrop, conversations about innovation often become surprisingly technology-centred. Discussions revolve around engineering, intellectual property, regulatory pathways and competitive advantages, all of which are important. Considerably less attention is devoted to understanding why healthcare would choose to adopt the technology in the first place.

That question is often reduced to a short paragraph labelled User Need or a diagram illustrating the Use Case. In reality, those two concepts define much more than the intended user or the clinical setting in which the device will be used. They describe the problem worth solving and the circumstances under which someone would willingly replace an established way of working with a new one.

A clearly articulated user need provides direction throughout development. It explains why the product should exist, who stands to benefit from it and what problem it genuinely solves. It also makes it much easier to understand what evidence will eventually matter and, perhaps more importantly, who that evidence is actually intended to convince.

Not every innovation asks healthcare to change in the same way, and that has profound implications for the evidence that will eventually be needed.

Some devices fit naturally into established clinical pathways. They improve an existing procedure, reduce complications or simplify a familiar workflow. Demonstrating safety, performance and clinical benefit may be sufficient to support both regulatory approval and clinical adoption.

More disruptive technologies rarely enjoy that luxury.

If implementation requires hospitals to redesign workflows, validate new technology within their quality systems, retrain staff or reconsider established treatment guidelines, the conversation quickly extends beyond regulatory compliance. Clinical evidence remains essential, but it becomes only one part of a much broader discussion involving health economics, implementation, reimbursement and organisational change.

The paradox is that much of the evidence capable of convincing healthcare to embrace a disruptive innovation cannot exist before the technology has entered routine clinical practice. Real-world outcomes, workflow efficiencies and many health economic benefits emerge only after adoption has already begun. Developers therefore find themselves in an uncomfortable position. The evidence needed to change clinical practice often depends on clinical practice having changed first.

Perhaps this is why discussions about clinical evidence sometimes begin in the wrong place. The first question is rarely what regulators will expect to see. More often, it should be what evidence clinicians, hospitals, professional societies, procurement teams and, ultimately, patients will need before they are willing to change established practice. Those are not always the same question, and the further a technology moves away from existing clinical routines, the wider that gap tends to become.

CE marking allows a product to enter the market. Adoption determines whether it becomes part of healthcare.

Medical technology changes healthcare only when healthcare decides it is worth changing.